Adjuvant Durvalumab Beneficial in Esophageal/GEJ Cancer?

Video
Conference|ASCO Annual Meeting: Gastrointestinal Cancer

Cancer Network spoke with Dr. Hirva Mamdani about the role and efficacy of adjuvant durvalumab in patients with Esophageal/GEJ Cancer.

Cancer Network spoke with Dr. Hirva Mamdani about the role and efficacy of adjuvant durvalumab in patients with Esophageal/GEJ Cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content
The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Roman Fabbricatore
June 18th 2025
Article

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer

SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer

Ariana Pelosci
June 3rd 2025
Article

Results from the ShorTrip trial found that SCRT plus chemotherapy regimens showed promising efficacy for patients with locally advanced rectal cancer.

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Tony Berberabe, MPH
June 2nd 2025
Article

Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.